



BioSyent Inc.

Q4/FY 2025 Results

MARCH 19, 2026

PRESENTED BY: RENÉ GOEHRUM
PRESIDENT AND CEO



DISCLAIMER

This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements within the meaning of Canadian Securities legislation and the forward-looking statements contained herein are made as at the date of this presentation and, accordingly, are subject to change after such date. Undue reliance should not be placed on such statements. These statements involve a number of risks and uncertainties including statements regarding the outlook for BioSyent Inc., business and operational results.

By nature, these risks and uncertainties could cause actual results to differ materially from what has been indicated. Factors that could cause actual results to differ materially from any forward-looking statement include, but are not limited to, failure to obtain governmental regulatory approvals, product recalls, competition from similar products and other factors including those risks and uncertainties identified above.

BioSyent Inc. undertakes no obligation to update publicly or otherwise revise any forward-looking information as a result of new information, future results or other such factors which affect this information, except as required by law.


All values in CAD unless otherwise indicated.






Sales, EBITDA and NIAT

Quarter ended December 31st (Q4)



Sales, EBITDA and NIAT

Full Year ended December 31st (FY)



Q4/FY 2025 Sales Summary (\$)


	Q4 '25 Sales (\$)	Q4 '25 vs. Q4 '24 (%)	FY '25 Sales (\$)	FY '25 vs. FY '24 (%)
Canadian Pharma (\$)	\$8,793k	+3%	\$37,144k	+13%
Cathejell®		-3%		+3%
Combogesic®		+5%		-18%
FeraMAX® Pd		+1%		+12%
Gelclair®		-15%		-39%
Inofolic®		+68%		+64%
RepaGyn®		+14%		+3%
Tibella® (Canada)		+21%		+32%
International Pharma (\$)	\$601k	+240%	\$3,736k	+302%
Legacy (\$)	\$278k	+278%	\$2,172k	+86%
Total Company (\$)	\$9,672k	+10%	\$43,052k	+23%

\$2.4 Million in additional 2025 sales contributed by Tibelia® international business (acquired in Sept 2024)

Fully Diluted Earnings per Share (TTM)

TTM and Quarterly Fully Diluted EPS (CAD)

62 Consecutive Profitable Quarters to Q4 2025



2025 Highlights



Tibelia Global

- FY 2025: First Tibelia® Global shipments made by BioSyent: ~\$2.4 million in incremental revenue
 - Further orders shipped in Q1 2026
- Mar/Jun/Sep/Dec 2025: Paid quarterly dividends of \$0.05/share (+11% increase vs. 2024)



- Apr 2025: FeraMAX® named #1 recommended iron supplement in Canada for **tenth** consecutive year
- FY 2025: 19,500 shares repurchased and cancelled under NCIB



YTD 2026 Highlights



- Mar 1, 2026: Completed Acquisition of Oral Science Inc.



- Mar 13, 2026: Paid quarterly dividend of \$0.055/share (+10% increase vs. 2025)



Geopolitics, Trade and Economy

- Uncertainty
- Armed conflicts
- Tariffs / Counter-Tariffs
- Inflationary impacts
- Impact on supply chains, global trade and economies



Acquisition of Oral Science



Acquisition by BioSyent Inc. of Privately-Owned Canadian Distributor of Specialized Healthcare Products for Dental Hygiene and Oral Health



- Share Purchase Agreement (SPA) closed on March 1, 2026
- 100% of issued Oral Science shares acquired from Shareholders, Founders of Oral Science
- Purchase price of \$25.5M (including \$6.3M working capital) + \$2.0M excess working capital + performance earn out + royalties on future sales of 1 product
 - Implied purchase multiple of ~6.2x EBITDA (FY 2025)
- Shareholders, founders and key management of Oral Science now also shareholders of BioSyent (234,192 shares / ~2% of RX issued shares)
- Oral Science Inc. now a wholly-owned subsidiary of BioSyent Inc.
- Oral Science will continue to operate now as stand-alone Oral Health Business unit of BioSyent
- Oral Science leadership continues to lead the Business Unit

Oral Science Overview

Growing, revenue-stage oral health company with a successful track record of developing, sourcing, marketing and distributing innovative dental hygiene and oral health products

- Founded in 2003
- Based in Brossard, Quebec, Canada with a national salesforce
- Revenue base:
 - 1/3 of sales from proprietary products and technologies
 - 2/3 of sales from in-licensed products

- 54% of sales from Canadian dental clinics
- 46% of sales from consumers at retail pharmacy and online from Oral Science

Financials (FY 2025 - ASPE):

- Revenues: \$30.9M
- EBITDA¹: \$ 4.1M

2018 – 2025 Revenue CAGR > 15%

Strong Balance Sheet for Future Growth

Financing of Acquisition


\$25.5M Purchase Price + \$2.0M Excess WC

- \$16.3M Liquid Cash
- \$ 8.0M Debt
 - \$6.0M Term Loan
 - \$2.0M Revolving Line Draw
- \$3.0M Common Shares
- \$0.2M RSUs

- Debt expected to be fully repaid in 2026


- Dividends and NCIB to continue
 - 10% dividend increase Q1 2026

Balance Sheet Assets – Pre and Post Closing



Strategic Rationale for Acquisition of Oral Science

- ✓ Transaction builds substantial scale in BioSyent's revenue and profit
- ✓ Strategic use of capital to accelerate growth and enhance resilience
- ✓ Derisks the business model with immediate diversification of BioSyent business, with new platform in tangential healthcare vertical
- ✓ Strengthened foundation for long-term growth with new customers and distribution channels to exploit



Going Forward



BioSyent will continue to invest in future growth of pharmaceutical + oral health platforms

FeraMAX®



10 YEARS IN A ROW



- Most recommended iron supplement in Canada - pharmacists and physicians - **10** consecutive years⁽¹⁾
- Continued innovation and expansion of FeraMAX® product line for iron health

(1) Based on Pharmacy Practice + Business, The Medical Post and Profession Santé 2025 Survey on OTC Counselling and Recommendations

Innovations, Product Launches and Acquisitions




Tibella®	Jul 2020	
FeraMAX® Pd	Oct 2020	
FeraMAX® Pd Therapeutic 150	Nov 2020	
Combogesic®	Dec 2020	
FeraMAX® Pd Powder 15	Oct 2021	
FeraMAX® Pd Maintenance 45	Mar 2023	
Inofolic®	Aug 2023	
Gelclair®	Nov 2023	
Tibelia® Global	Sep 2024	
Oral Science	Mar 2026	
New endocrinology asset	TBD	
FeraMAX® Pd products in development	TBD	

16 Years of Profitable Growth (and Counting!)




Tibelia Global



f/d shares: 14,336,194 11,831,378


ProForma 2025 with Oral Science



f/d shares: 14,336,194 11,831,378

Cash Balance & Return on Equity (“RoE”)

Full Year ended December 31




- 2025 Cash from Operations; **\$9.0M**
- 2025 NCIB share buybacks: **\$0.2M**
- 2025 Net Dividends: **\$2.3M**
- Dec 31/25 Working Capital of **\$32.6M**
- Execution of strategy drives TTM RoE of **24%**
- **\$16.3M** Cash deployed in Oral Science acquisition Mar 2026



Capital Allocation linked to Strategy

First use of capital is to generate revenue/profit growth & portfolio diversification.



- 7 new product launches in Canada since July 2020
- Tibelia[®] / Tibella[®] (tibolone) Global Acquisition in Sept 2024
- Oral Science Acquisition Mar 2026

Stock Information

As at March 18, 2026

Exchange & Trading Symbol	TSXV: RX
Mar 18, 2026 Closing Stock Price (CAD) (TSXV):	\$15.31
52 Week Hi/Low (TSXV):	\$15.80 / \$9.20
Issued Common Shares:	11,709,639
Treasury – RSU Shares in Trust	(212,192)
Outstanding Common Shares:	11,497,447
Options Outstanding	104,955
RSUs Outstanding	<u>228,976</u>
Fully Diluted Common Shares:	<u>11,831,378</u>
P/E Ratio :	20.74*
EV/EBITDA ⁽¹⁾ :	12.79*

*Based on BioSyent stand-alone 2025 earnings (excludes Oral Science)

Reconciliation of EBITDA to NIAT

1. **EBITDA** is a Non-IFRS Financial Measure. The term EBITDA does not have any standardized meaning under International Financial Reporting Standards (IFRS) and therefore may not be comparable to similar measures presented by other companies. The Company defines EBITDA as earnings before interest income or expense, income taxes, depreciation and amortization.

A reconciliation of EBITDA to NIAT for the three months and twelve months ended December 31, 2025 and 2024 is provided in the table below:

	Fourth Quarter (Q4) Ended December 31		Full Year (FY) Ended December 31	
	2025	2024	2025	2024
EBITDA	2,528,561	2,241,112	12,122,756	9,343,012
Add: Interest Income	187,767	260,088	809,100	1,088,586
Less:				
Depreciation - Property, Equipment	(70,964)	(72,113)	(272,299)	(281,220)
Amortization of Intangible Assets	(155,498)	(164,207)	(580,192)	(308,728)
Interest Expense	(11,478)	(13,971)	(49,353)	(59,152)
Income Tax Expense	(486,600)	(637,715)	(3,017,780)	(2,512,394)
NIAT	1,991,788	1,613,194	9,012,232	7,270,104



- ✓ PROFITABLE.
- ✓ WELL CAPITALIZED.
- ✓ GROWTH ASSETS.
- ✓ FOCUSED ON LONG-TERM GROWTH AND TOTAL SHAREHOLDER RETURN.

